eCite Digital Repository

Dimethyl fumarate and its esters: a drug with broad clinical utility?

Citation

Kourakis, S and Timpani, CA and de Haan, JB and Gueven, N and Fischer, D and Rybalka, E, Dimethyl fumarate and its esters: a drug with broad clinical utility?, Pharmaceuticals, 13, (10) pp. 1-15. ISSN 1424-8247 (2020) [Substantial Review]


Preview
PDF
Pending copyright assessment - Request a copy
520Kb
  

DOI: doi:10.3390/ph13100306

Abstract

Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.

Item Details

Item Type:Substantial Review
Keywords:dimethyl fumarate, metabolic disease, neurodegeneration, clinical application, dimethyl fumarate, disease, fumaric acid esters, oxidative stress, inflammation, Nrf2, disease
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Pharmaceutical sciences
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Gueven, N (Dr Nuri Guven)
ID Code:141341
Year Published:2020
Web of Science® Times Cited:11
Deposited By:Pharmacy
Deposited On:2020-10-15
Last Modified:2021-04-22
Downloads:0

Repository Staff Only: item control page